Michael R Liebowitz
Overview
Explore the profile of Michael R Liebowitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
2523
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McElroy S, Coloma P, Berger B, Guerdjikova A, Joyce J, Liebowitz M, et al.
Int J Eat Disord
. 2023 Aug;
56(11):2120-2130.
PMID: 37584285
Objective: This Phase II, placebo-controlled, double-blind study investigated the efficacy, safety, and tolerability of nivasorexant in the treatment of adults with moderate to severe binge-eating disorder (BED). Methods: Adults meeting...
2.
Monti L, Liebowitz M
CNS Spectr
. 2020 Oct;
27(1):66-72.
PMID: 33092667
In this review, we describe proposed circuits mediating the mechanism of action of pherines, a new class of synthetic neuroactive steroids with demonstrated antianxiety and antidepressant properties, that engage nasal...
3.
Schmidt M, Liebowitz M, Stein M, Grunfeld J, Van Hove I, Simmons W, et al.
Neuropsychopharmacology
. 2020 Oct;
46(5):1004-1010.
PMID: 33070154
JNJ-42165279 is a selective inhibitor of fatty acid amide hydrolase (FAAH), the enzyme responsible for the degradation of fatty acid amides (FAA) including anandamide (AEA), palmitoylethanolamide (PEA), and N-oleoylethanolamide (OEA)....
4.
Pereira S, Brennan E, Patel A, Moran M, Wallier J, Liebowitz M
Int Clin Psychopharmacol
. 2020 Aug;
36(1):54-57.
PMID: 32804743
Patients with treatment-resistant depression (TRD) treated with esketamine nasal spray commonly experience transient symptoms of dissociation. Manifestations of dissociation, such as feelings of detachment from the environment, can cause considerable...
5.
Liebowitz M, Careri J, Blatt K, Draine A, Morita J, Moran M, et al.
Depress Anxiety
. 2017 Nov;
34(12):1164-1172.
PMID: 29166552
Background: Major Depressive Disorder (MDD) and Social Anxiety Disorder (SAD) are highly comorbid, yet the combined condition has not been subject to any placebo-controlled treatment trials. This study reports a...
6.
Cohen J, Drabick D, Blanco C, Schneier F, Liebowitz M, Heimberg R
J Anxiety Disord
. 2017 Nov;
52:79-87.
PMID: 29102818
Social anxiety disorder (SAD) is highly prevalent and associated with high levels of impairment and distress. Therapies for SAD leave many patients symptomatic at the end of treatment, and little...
7.
Rodebaugh T, Levinson C, Langer J, Weeks J, Heimberg R, Brown P, et al.
Psychiatry Res
. 2017 Feb;
250:297-301.
PMID: 28199950
Social anxiety disorder symptoms are generally proposed to be related to broad temperamental vulnerabilities (e.g., a low level of approach and high level of avoidance temperament), specific psychological vulnerabilities (e.g.,...
8.
Liebowitz M, Hanover R, Draine A, Lemming R, Careri J, Monti L
Depress Anxiety
. 2016 Aug;
33(12):1081-1089.
PMID: 27561175
Background: There are no medications approved for as-needed use for feared situations for individuals with social anxiety disorder (SAD). In the present study, intranasal PH94B was provided for use as...
9.
Careri J, Draine A, Hanover R, Liebowitz M
Prim Care Companion CNS Disord
. 2016 Apr;
17(6).
PMID: 27057414
Objective: To examine the efficacy, safety, and tolerability of vilazodone for subjects (aged 18-75 years) with generalized social anxiety disorder. Method: Forty-four subjects with generalized social anxiety disorder (DSM-IV-TR criteria)...
10.
Cohen J, Potter C, Drabick D, Blanco C, Schneier F, Liebowitz M, et al.
Psychiatry Res
. 2015 Apr;
228(1):65-71.
PMID: 25920804
Therapies for social anxiety disorder (SAD) leave many patients symptomatic at the end of treatment and little is known about predictors of treatment response. This study investigated the predictive relationship...